Edgardo S. Santos, MD, FACP, FASCO

Prof. Edgardo S. Santos, MD, FACP, FASCO


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2006 in Liver International
Verified
Journal Article
Closed access
PDF file
Edgardo S. Santos, MD, FACP, FASCOEdgardo S. Santos, MD, FACP, FASCO
Edgardo S. Santos, MD, FACP, FASCO
LALeopoldo R. Arosemena
Leopoldo R. Arosemena
LRLuis E. Raez
Luis E. Raez
COChristopher O'Brien
Christopher O'Brien
ARArie Regev
Arie Regev

22 August 2022 in JCO Global Oncology
Verified
Journal Article
Open access
CCChristian Caglevic
Christian Caglevic
Christian RolfoChristian Rolfo
Christian Rolfo
IGIgnacio Gil-Bazo
Ignacio Gil-Bazo
ACAndres Cardona
Andres Cardona
JSJorge Sapunar
Jorge Sapunar
CZChristoph Zielinski
Christoph Zielinski
On February 24, 2022, a war began within the Ukrainian borders. At least 3.0 million Ukrainian inhabitants have already fled the country. Critical infrastructure, including hospitals, has been damaged. Children with cancer were urgently transported to foreign countries, in an effort to minimize interruption of their life-saving treatments. Most adults did not have that option. War breeds cancer—delaying diagnosis, preventing treatment, and increasing risk. We project that a modest delay in care of only 4 months for five prevalent types of cancer will lead to an excess of over 3,600 cancer deaths in the subsequent years. It is critical that we establish plans to mitigate that risk as soon as possible.

3 March 2020 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
Edgardo S. Santos, MD, FACP, FASCOEdgardo S. Santos, MD, FACP, FASCO
Edgardo S. Santos, MD, FACP, FASCO
Introduction: The recent approvals of checkpoint inhibitors as single agents or in combination with chemotherapy with programmed death ligand 1 expression of < or ≥1% have challenged clinicians when it is time to begin a metastatic lung cancer patient in second-line therapy. The advantages given by immunotherapy over conventional chemotherapy such as improved overall survival and a better toxicity profile make the second-line clinical scenario more difficult for a patient who faces a likely inferior regimen as well as toxicity which may significantly impact the quality of life. Areas covered: Options given today by the National Comprehensive Cancer Network are very limited, and essentially, we go back to conventional cytotoxic agents alone or in combination with biological agents if possible. In this article, we discuss the actual treatment available for this difficult scenario and some of the ongoing trials which aim to address this dilemma. Expert commentary: This is an unmet need in lung cancer management; we need a better understanding of the mechanism of resistance to immunotherapy so we can target them once the patient moves to second-line treatment.

1 December 2004 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
Edgardo S. Santos, MD, FACP, FASCOEdgardo S. Santos, MD, FACP, FASCO
Edgardo S. Santos, MD, FACP, FASCO
LRLuis E. Raez
Luis E. Raez
PEPaula Eckardt
Paula Eckardt
TDTeresa DeCesare
Teresa DeCesare
CWClarence C. Whitcomb
Clarence C. Whitcomb
GBGerald E. Byrne
Gerald E. Byrne
A bone marrow (BM) aspiration and biopsy is often believed to be a needed diagnostic procedure in the work-up of patients with fever of unknown origin (FUO), especially in the setting of AIDS. Is it worthwhile to proceed with this invasive diagnostic method? Clinical information obtained on 104 patients in whom AIDS had been previously diagnosed and who had been admitted with a presumptive diagnosis of FUO was retrospectively analyzed. Seventy-two cases met the inclusion criteria. A BM aspiration and biopsy had a low sensitivity as a diagnostic tool even in patients who had abnormal hematologic parameters. BM biopsy was also not helpful in diagnosing non-Hodgkin lymphoma (NHL) cases in this study. Although the incidence of NHL has risen since the emergence of HIV, the predominant types of lymphoma seen in AIDS patients are intermediate/high-grade lymphomas rather than low grade, and consequently, the incidence of BM involvement is low, decreasing the sensitivity of a BM biopsy as a diagnostic tool. These observations were validated in this study. The majority of BM biopsies in this series revealed diagnostic features of infections. This observation can likely be related to the high prevalence of HIV/AIDS patients in this community and opportunistic infections associated with this disease.

9 October 2018 in Targeted Oncology
Verified
Journal Article
Open access
PDF file
LRLuis E Raez
Luis E Raez
Edgardo S. Santos, MD, FACP, FASCOEdgardo S. Santos, MD, FACP, FASCO
Edgardo S. Santos, MD, FACP, FASCO

1 October 2004 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
Edgardo S. Santos, MD, FACP, FASCOEdgardo S. Santos, MD, FACP, FASCO
Edgardo S. Santos, MD, FACP, FASCO
JRJoseph D Rosenblatt
Joseph D Rosenblatt
MGMark Goodman
Mark Goodman
The treatment of hematologic malignancies has progressed in the last few years. Identification of new pathways and target molecules in leukemia has ushered in a promising new era of therapy. Ras mutations have recently been implicated in the pathogenesis of acute leukemia, and inhibition of Ras signaling through the use of farnesyltransferase inhibitors (FTIs) has shown promise in early trials in acute myeloid leukemia (AML). Responses have not correlated with the presence of Ras mutations, suggesting that novel pathways are involved. In several early trials, FTIs have shown activity as single agents in poor-risk AML, suggesting a potential role in combination with standard chemotherapy. FTIs are now being tested in other clinical settings, such as myelodysplasia, chronic myelogenous leukemia and multiple myeloma, with encouraging preliminary activity.